Concurrent frontline nivolumab and gemcitabine-cisplatin followed by nivolumab maintenance therapy elicited OS and PFS benefits vs gemcitabine-cisplatin alone in patients with previously untreated, metastatic or unresectable urothelial carcinoma.

Related Keywords

Netherlands , Amsterdam , Noord Holland , Michiels Van , , Netherlands Cancer Institute , Concurrent Frontline Nivolumab And Gemcitabine Cisplatin , Urothelial Carcinoma , Checkmate 901 Study , Nct03036098 , Michiels Van Der Heijden , D , Phd ,